Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:item
|
| gptkbp:appointed_by |
healthcare professional
adults elderly patients oral tablet patients with heart conditions patients with clotting disorders |
| gptkbp:approves |
gptkb:1954
gptkb:FDA |
| gptkbp:brand |
gptkb:Jantoven
gptkb:warfarin_sodium |
| gptkbp:caused_by |
gptkb:purple_toe_syndrome
skin necrosis |
| gptkbp:contraindication |
pregnancy
severe liver disease active bleeding |
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:dosage_form |
gptkb:tablet
10 mg 1 mg 5 mg 2 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Coumadin
|
| gptkbp:ingredients |
gptkb:warfarin
doctors patients with atrial fibrillation patients at risk of thrombosis patients with mechanical heart valves patients with previous blood clots |
| gptkbp:interacts_with |
antibiotics
antidepressants certain foods NSAI Ds |
| gptkbp:is_available_in |
various strengths
different formulations |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
blood tests
INR levels |
| gptkbp:is_part_of |
anticoagulation therapy
post-surgical care cardiovascular disease management long-term anticoagulation management |
| gptkbp:is_used_for |
preventing blood clots
|
| gptkbp:is_used_in |
stroke prevention
thrombosis prevention myocardial infarction prevention venous thromboembolism treatment |
| gptkbp:side_effect |
nausea
bruising vomiting diarrhea bleeding |
| gptkbp:suitable_for |
patients with recent surgery
patients with active peptic ulcer disease patients with certain genetic mutations patients with uncontrolled hypertension |
| gptkbp:used_in |
gptkb:deep_vein_thrombosis
gptkb:atrial_fibrillation pulmonary embolism heart valve replacement |